



HAL
open science

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma

Marion Haas, Gersende Caron, Fabrice Chatonnet, Stéphane Manenti, Elina Alaterre, Julie Devin, Céline Delaloy, Giulia Bertolin, Roselyne Viel, Amandine Pignarre, et al.

► To cite this version:

Marion Haas, Gersende Caron, Fabrice Chatonnet, Stéphane Manenti, Elina Alaterre, et al.. PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma. *Blood*, 2022, 139 (15), pp.2316-2337. 10.1182/blood.2021014011 . hal-04822853v2

HAL Id: hal-04822853

<https://hal.science/hal-04822853v2>

Submitted on 6 Dec 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



IMMUNOBIOLOGY AND IMMUNOTHERAPY

PIM2 kinase has a pivotal role in plasmablast generation and plasma cell survival, opening up novel treatment options in myeloma

Marion Haas,^{1,2} Gersende Caron,^{1,2} Fabrice Chatonnet,^{1,2} Stéphane Manenti,³ Elina Alaterre,⁴ Julie Devin,⁴ Céline Delaloy,¹ Giulia Bertolin,⁵ Roselyne Viel,⁶ Amandine Pignarre,^{1,2} Francisco Llamas-Gutierrez,⁷ Anne Marchalot,⁸ Olivier Decaux,^{1,9} Karin Tarte,^{1,2} Laurent Delpy,⁸ Jérôme Moreaux,⁴ and Thierry Fest^{1,2}

¹Université de Rennes 1, INSERM, Établissement Français du Sang de Bretagne, Unité Mixte de Recherche (UMR)_S1236, Rennes, France; ²Laboratoire d'hématologie et immunologie, Pôle de Biologie, Centre Hospitalier Universitaire, Rennes, France; ³Université de Toulouse, Centre National de la Recherche Scientifique (CNRS) Equipe de Recherche Labellisée (ERL) 5294, INSERM U1037, Centre de Lutte Contre le Cancer, Toulouse, France; ⁴Institut de Génétique Humaine, UMR 9002 CNRS-UM, Pôle de biologie, Centre Hospitalier Universitaire, Montpellier, France; ⁵Université de Rennes, CNRS, Institut de Génétique & Développement de Rennes, UMR 6290, Rennes, France; ⁶Plateforme H2P2, Rennes, France; ⁷Laboratoire d'Anatomie Pathologique, Pôle de Biologie, Centre Hospitalier Universitaire, Rennes, France; ⁸Université de Limoges, UMR CNRS 7276, INSERM U1262, Limoges, France; and ⁹Service d'hématologie clinique, Centre Hospitalier Universitaire, Rennes, France

KEY POINTS

- B-cell commitment into PBs activates PIM2 via STAT3, which promotes G1/S transition and inhibits caspase 3–driven apoptosis.
- PC survival requires strong expression of PIM2 and its inhibition exhibits a synergistic effect with MCL1-inhibitor in myeloma.

The differentiation of B cells into plasmablasts (PBs) and then plasma cells (PCs) is associated with extensive cell reprogramming and new cell functions. By using specific inhibition strategies (including a novel morpholino RNA antisense approach), we found that early, sustained upregulation of the proviral integrations of Moloney virus 2 (PIM2) kinase is a pivotal event during human B-cell in vitro differentiation and then continues in mature normal and malignant PCs in the bone marrow. In particular, PIM2 sustained the G1/S transition by acting on CDC25A and p27^{Kip1} and hindering caspase 3–driven apoptosis through BAD phosphorylation and cytoplasmic stabilization of p21^{Cip1}. In PCs, interleukin-6 triggered PIM2 expression, resulting in antiapoptotic effects on which malignant PCs were particularly dependent. In multiple myeloma, pan-PIM and myeloid cell leukemia-1 (MCL1) inhibitors displayed synergistic activity. Our results highlight a cell-autonomous function that links kinase activity to the newly acquired secretion ability of the PBs and the adaptability observed in both normal and malignant PCs. These findings should finally prompt the reconsideration of PIM2 as a therapeutic target in multiple myeloma.

Introduction

Before becoming plasma cells (PCs), the B cells first pass through an immature, proliferative plasmablast (PB) stage. The PBs emerge after major changes in B-cell morphology, epigenome-sustained expression profile, and life span.^{1,2} This tightly regulated cell metamorphosis can be hijacked by oncogenic alterations that drive malignant transformation. Although there is a large body of data on normal B-cell differentiation, studies of B-cell malignancies have shown that our understanding of normal B-cell function is incomplete,³ in particular for identifying specific factors and determining their spatiotemporal involvement in the molecular modifications underlying B-cell metamorphosis.

We have reported that the emergence of human PBs is associated with large-scale methylome modifications, with the local acquisition of active epigenetic marks on PC identity genes during a committal step in which some activated B cells differentiate into PBs.⁴ These highly proliferative, activated, committed B cells

(hereafter referred to as preplasmablasts [prePBs]) are characterized by the silencing of the interleukin-4 (IL-4)/STAT6 pathway and thus downregulation of CD23 surface marker expression.⁵ By focusing on this feature, a comparative RNA sequencing (RNA-seq) analysis of prePBs allowed us to identify here a striking increase in expression of the gene encoding the proviral integrations of Moloney virus 2 (PIM2) serine/threonine kinase. The 3 members of the PIM kinase family are known to phosphorylate numerous substrates involved in crucial cellular functions.⁶ Dysregulated expression of PIM kinases has been reported in several cancers, including multiple myeloma (MM).^{7,8} Surprisingly, PIM2 has never been analyzed in the context of normal B-cell differentiation. In mouse pro-B cells, Pim2 expression depends on growth factor–induced transcription,^{9,10} which justifies further research in the context of PC differentiation.

The present study evaluated the effects of PIM2 on PB generation and PC survival. We found that the B-cell commitment activates the transcription of *PIM2* in a STAT3-dependent manner,

which leads to a strong increase in the protein's expression level and functional activity. We assessed the biological effects of PIM2 in primary B cells by comparing a normal culture with 2 conditions in which the functions of PIM2 were altered by either stopping gene expression or blocking kinase activity. Along with PIM2-mediated BAD phosphorylation, we detected effects on p21^{Cip1}, CDC25A, and p27^{Kip1}. During the final step in differentiation, these effects all promote cell survival and entry into the S phase of the cell cycle. Moreover, PIM2 was found to be strongly expressed in quiescent mature PCs and essential for cell survival. In a malignant setting, PCs are addicted to PIM2, and targeting this kinase was synergistic with BH3 mimetics, offering new treatment options for MM.

Methods

Purification of primary B cells, cell culture, cell cycle assessment, immunophenotyping, cell sorting, and protein assays

Procedures and methods are detailed in the supplemental Methods (available on the *Blood* Web site).

Cell line culture and viability assays

Human myeloma cell lines were obtained and cultured as described previously.¹¹ Viability was assessed for cells treated with selected compounds: AZD1208 and AZD5991 (Selleck Chemicals). CellTiter-Glo Luminescent Assay kit (Promega) was used as described by the manufacturer. Results were normalized to the samples without treatment, and synergy scores were calculated by using the Bliss method¹² as described by Combès et al.¹³

Primary MM cells

Samples were collected with the approval of the institutional research board from Rennes University Hospital and in accordance with the Declaration of Helsinki. Mononuclear cells were isolated by using Ficoll density gradient centrifugation. Samples were cultured in the presence of 2 ng/mL of IL-6. Cell cytotoxicity was evaluated by using flow cytometry to determine the percentage of viable CD138⁺ cells.

Splice-switching antisense oligonucleotide experiments

Inhibition of PIM2 expression is enabled by the use of a vivo-morpholino PIM2 splice-switching antisense oligonucleotide (SSO-PIM2) from Gene Tools, LLC. An irrelevant vivo-morpholino standard oligonucleotide was used as control (SSO-CTL). PIM2 messenger RNA (mRNA) knockdown efficiency was evaluated by reverse transcription polymerase chain reaction (RT-PCR) to simultaneously identify full-length (286 pb) and alternatively spliced (176 bp) PIM2 mRNAs on an agarose gel. Quantification of inhibition was also performed by quantitative RT-PCR with exon 2 targeting primers and verified at the protein level by immunoblot.

RNA-seq, assay for transposase-accessible chromatin sequencing, and data accessibility

Procedures and analysis methods have been described previously.⁵

Results

The emergence of PIM2 expression during PB commitment

To identify genes regulated specifically during the final commitment step, we used our previously described *in vitro* differentiation model with human naive B cells generating 4 cell populations on day 6 (D6) (Figure 1A).¹⁴ The RNA-seq data (confirmed by quantitative PCR assays) revealed a striking elevation of *PIM2* mRNA expression (but not *PIM1* or *PIM3* expression) in prePBs (P2/CD23⁻ population) and PBs (P1 population), relative to B cells diverted from differentiation (P2/CD23⁺ and P3 populations) (Figure 1B; supplemental Figure 1A). In an unsupervised analysis, the results of single-cell quantitative RT-PCRs in P2/CD23⁻ vs P2/CD23⁺ cell populations ranked *PIM2* as the most discriminating gene, ahead of *PRDM1* (Figure 1C; supplemental Figure 1B). Analysis of our RNA-seq data sets showed that *PIM2* was in the top 150 genes characterizing PBs, relative to noncommitted B-cell populations (supplemental Figure 1C).⁵ The protein levels correlated perfectly with gene expression levels, with strong PIM2 expression in prePBs and PBs (Figure 1B). With regard to human tonsil-derived cell populations, CD19⁺IgD⁻CD38^{bright} PBs expressed higher levels of PIM2 than other B-cell populations (Figure 1D).

To determine whether *PIM2* gene expression is coupled to genomic changes during PC differentiation, we analyzed our previously published data sets^{4,5} and ENCODE annotations (<https://www.encodeproject.org>). An assay for transposase-accessible chromatin sequencing (ATAC-seq) showed that the open regions in prePBs and PBs included the *PIM2* promoter and an upstream enhancer. This latter overlaps with a region denoted as interacting physically with the *PIM2* promoter in the FANTOM5 database¹⁵ and with a superenhancer described in PBs and MM PCs (Figure 1E).¹⁶ The comparative analysis of genome-wide 5hmC marks in naive B cells vs PBs showed that read densities increased in both the identified ATAC-seq regions and the body of the *PIM2* sequence; this action testified to the enhancer functions and activation in PBs, as has been shown for PB/PC identity genes (Figure 1E; supplemental Figure 1D).⁴

ATAC-seq analysis showed that the time course of promoter opening did not match the gene expression pattern; this disparity suggests that a transcriptional regulator is present in the *PIM2* locus (Figure 1E; supplemental Figure 1D). By chromatin immunoprecipitation sequencing of human activated B cells, we identified a BACH2 binding site in the *PIM2* promoter.¹⁷ BACH2 inhibition experiments revealed a subsequent increase in PIM2 expression and thus confirmed that BACH2 acts as a repressor (Figure 1F). Furthermore, the stimulation of PBs with IL-10, IL-21, and (to a lesser extent) IL-6 resulted in a sharp induction of PIM2 expression (Figure 1G). Given that all 3 cytokines are known to recruit the STAT3 pathway, we exposed the cells to the STAT3 inhibitor C188-9; this led to the dose-dependent repression of PIM2 expression (Figure 1G-H). In contrast, IL-2 (which recruits STAT5) and interferon- α were weak inducers. Because STAT3 signaling also induces *PRDM1*/BLIMP1 expression,¹⁸ we wondered if PIM2 was one of the downstream factors of BLIMP1. In fact, under IL-10 (or IL-21 [data not shown]) stimulation, *PRDM1* was induced but later than *PIM2* expression (supplemental Figure 1E). In addition, siPRDM1 experiments on primary B cells and U266 MM cells




Figure 1.




Figure 1. PIM2 expression and regulation during normal B-cell differentiation. (A) Using a 2-step cell culture process, VPD-labeled naive B cells (NBCs) were differentiated into the cell populations P1, P2, and P3. P2 cells were subdivided into P2/CD23⁺ and P2/CD23⁻ subsets. The PB P1 population arose from the P2/CD23⁻ subset. (B) Left: *PIM2* RNA-seq results on D4 or day 5 (D5) in the various cell populations. Data are presented as the mean \pm SD, $n = 3$. Right: *PIM2* mRNA expression in the various cell populations on D6. mRNA data are presented as the median (range); $n = 6$. Bottom, *PIM2* protein expression in all cell populations, from day 0 (D0) to D6. (C) A single-cell quantitative RT-PCR heat map of the expression of 31 genes in P2/CD23⁻ vs P2/CD23⁺ cell subsets; the red arrow indicates *PIM2* mRNA expression. (D) *PIM2* mRNA expression (top) and protein expression (bottom) in different tonsil-derived B-cell populations. mRNA data are presented as the median (range), $n = 7$. (E) The Integrative Genomic Viewer genome browser window, showing several features around the *PIM2* locus. Colored tracks at the top are our RNA-seq and ATAC-seq data.⁵ ATAC-seq showed that the open regions included the *PIM2* promoter and an upstream enhancer that physically interact together. ATAC-seq regions close to *PIM2* comprise transcription factor-binding sites for relevant factors such as STAT3, according to ENCODE data, and also BACH2, including one we have identified by chromatin immunoprecipitation.¹⁷ 5hmC marks are identified in ATAC-seq regions and the body of the *PIM2* sequence in PBs.⁴ Details are provided in supplemental Figure 2A. (F) Levels of *BACH2* and *PIM2* mRNA expression (left) and protein expression (right) in D4^{lo} cells after transfection with siBACH2 on day 2 (D2). mRNA data are presented as the mean \pm SD, $n = 4$. (G) On D5, PBs were sorted, starved, and then stimulated with the indicated cytokines. Left: *PIM2* mRNA expression after 4 hours (pink) and 16 hours (red). For each time point, the results were normalized against the nonstimulated condition (set arbitrarily to 1 [in gray]). mRNA data are presented as the mean \pm SD, $n = 5$. Right: *PIM2*, pSTAT3 and pSTAT5 protein expression after 16 hours. (H) On D5, PBs were sorted, starved, and then treated with increasing doses of a STAT3 inhibitor (Stat3i) 1 hour before the addition of IL-10. *PIM2* mRNA expression (left) and protein expression (right) were assessed 4 hours after the addition of IL-10. mRNA data are presented as the mean \pm SD, $n = 5$. (I) Regulation of *PIM2* expression during B-cell differentiation. At the start of B-cell differentiation and despite the open chromatin on the promoter and on other regulatory regions, *PIM2* expression is constrained by BACH2. BACH2 expression then declines throughout the differentiation process, whereas T follicular helper-driven molecules stimulate STAT3 signaling. Both events promote the burst in *PIM2* expression in cells committed to differentiation into PBs. Statistical significance was evaluated by using the Mann-Whitney *U* test (panels C, F, G, and H) or the Kruskal-Wallis test (panel H). * $P < .05$, ** $P < .01$, *** $P < .001$. CpG, cytosine guanine dinucleotide; GC, germinal center; IgM, immunoglobulin M; MBC, memory B cell; ns, not significant; siCTL, small interference (si) RNA control (CTL); TFs, transcription factors; VPD, violet cell proliferation dilution. Further details are presented in supplemental Figure 1.




Figure 2.




Figure 2. Specific inhibition of PIM2 affects the generation of PBs. (A) Left: On D6, total blood B cells were differentiated into 2 different cell populations: CD23⁺ aBCs and PBs. Right: *PIM2* mRNA expression and protein expression in CD23⁺ aBCs and PBs on D6. Data are presented as the median (range), n = 10. (B) Diagram illustrating the mode of action of SSO-PIM2. Specific inhibition of PIM2 was performed by specifically blocking *PIM2* gene expression using a novel antisense RNA strategy based on a morpholino SSO. In line with a previously described forced-splicing-dependent nonsense-mediated decay approach to knockdown,^{56,57} the SSO targets the 5' splice site of exon 2 of *PIM2*, induces out-of-frame exon skipping, and generates a premature stop codon in exon 4. This latter eventually triggers nonsense-mediated decay or generates a truncated, nonfunctional protein. Details are provided in the supplemental Methods. (C) Activated B cells were treated with various doses of SSO-PIM2 from D4 to D6. Top, *PIM2* mRNA expression levels were compared with those in a control experiment, set arbitrarily to 100% (mean ± SD, n = 4) (top section). The agarose gel from the *PIM2* PCR shows the exon skipping (bottom section). Dose escalation experiments allowed us to select an SSO-PIM2 concentration of 2 μM for the subsequent experiments in the in vitro model. Bottom, PIM2 protein expression was assessed by western blot on D6 after PIM2 inhibition with an increasing dose of SSO-PIM2. (D) *PIM2* mRNA expression (mean ± SD, n = 6) (left) and protein expression (right), as determined by immunoblotting and immunofluorescence in CD23⁺ aBCs and PBs after PIM2 inhibition with SSO-PIM2 (2 μM). Sytox (blue) stains the nucleus. Scale bar: 10 μm. (E-F) On D4, cells were treated with SSO-PIM2 (E) or increasing doses of PIMi (F). On D6, analysis of cell differentiation was performed in the model described in panel A. Proportion of CD23⁺ aBCs (CD23⁺/CD38^{low} cells) and PBs (CD38^{high}/CD23⁻ cells) and the absolute number of each cell population were assessed by flow cytometry according to the gating strategy described in supplemental Figure 2D. Left: The absolute number of PBs and CD23⁺ aBCs obtained on D6 after PIM2 inhibition, compared with controls. Data are presented as the mean ± SD, n = 8. Right: One representative result of the proportion of PBs on D6 (evaluated by using flow cytometry) after PIM2 inhibition, compared with controls. Statistical significance was evaluated by using Mann-Whitney *U* (panel A), Wilcoxon (panel E), and Friedman (panel F) tests. **P* < .05, ***P* < .01, ****P* < .001, *****P* < .0001. CpG, cytosine guanine dinucleotide; D0, day 0; D2, day 2; DMSO, dimethyl sulfoxide; NT, no treatment; ns, not significant. Further details are presented in supplemental Figure 2.

showed no modifications in *PIM2* expression, unlike the well-known target genes of BLIMP1 (supplemental Figure 1F-G),^{19,20} consistent with previous data in pre-PB/PBs from knockout *Prdm1* mice.²¹ Finally, by chromatin immunoprecipitation-quantitative PCR on PBs and in RPMI8226 MM cells as well, we confirmed the

binding of phosphorylated-STAT3 (pSTAT3) on the *PIM2* promoter, as well as on the intron 3 of *PIM2* locus (predicted enhancer region) and in the putative enhancer located downstream of the gene (Figure 1E; supplemental Figure 1H). Altogether, these results confirmed that PIM2 respond directly to STAT3 and not via




Figure 3.




Figure 3. (Continued).

BLIMP1. Interestingly, although PIM2-positive PBs were pSTAT3 positive in the absence of BACH2, PIM2-negative/BACH2-positive CD23⁺ activated B cells (CD23⁺ aBCs) were also positive for pSTAT3, suggesting that the downregulation of BACH2 is required before STAT3 can induce PIM2 expression (supplemental Figure 1).

Taken as a whole, our results show that PB differentiation is associated with a sharp elevation of PIM2 kinase expression; this elevation requires the removal of BACH2 repression and STAT3 activation (Figure 1).

PIM2 is required for the differentiation of B cells into PBs

To determine the functional involvement of PIM2 in the commitment step and obtain further differentiated cells on D6, we focused our study on resulting PBs and CD23⁺ post-activated B cells (hereafter referred to as CD23⁺ aBCs), which both differed markedly in their PIM2 expression (Figure 2A). In subsequent experiments, we compared a normal culture setting with conditions in which PIM2 was inhibited on day 4 (D4) by exposure to the small-molecule pan-PIM inhibitor AZD1208 (hereafter referred to as PIMi) or by specifically blocking *PIM2* gene expression using a novel antisense RNA strategy based on a morpholino SSO (Figure 2B). Cells cultured with SSO-PIM2 exhibited a dose-dependent decrease in full-length *PIM2* mRNA, the expression of a weaker band corresponding to alternatively spliced mRNAs lacking exon 2, as well as PIM2 protein expression (Figure 2C). At the selected dose of 2 μ M, PIM2 expression was almost completely abrogated in PBs, without affecting *PIM1* expression (Figure 2D; supplemental Figure 2B). Although exposure to SSO-PIM2 did not affect the expression of key transcription factors involved in B-cell differentiation (supplemental Figure 2C), PIM2 knockdown led to a sharp decrease in PB generation (Figure 2E-F; supplemental Figure 2D). In contrast, CD23⁺ aBCs were not affected. These results suggest that PIM2 kinase activity sustains the PB commitment.

PIM2 sustains the G1/S transition through an effect on CDC25A and p27^{Kip1}

A comparison of gene expression in prePBs vs noncommitted B-cell populations evidenced the downregulation of *SMAD3* in the former population. Accordingly, prePBs upregulated

CDC25A, *CCND2*, and *CDK6* expression (supplemental Figure 3A), reentered the cell cycle, and gave rise to PBs.⁴ At D6, two days after inhibition of PIM2, the S phase decreased, and cells accumulated in G0/G1 (Figure 3A; supplemental Figure 3B). In parallel, the number of generated PBs decreased (Figure 2E-F), regardless of effects on cell death as shown by the QVD-OPH condition (supplemental Figure 3B-C). Moreover, after short exposure to PIMi (12 hours), the decrease of S phase was already observable in the absence of an effect on apoptosis (supplemental Figure 3B-D). Altogether, these results suggest that PIM2 promotes the G1/S transition independently of the cell death induction. We next performed cell cycle synchronization experiments in the XG21 MM cell line. As expected, unlike the control conditions, in which cells reached the S phase 6 hours after release, PIM2 inhibition was associated with blockage of the cells in G1 (supplemental Figure 3E).

The phosphatase *CDC25A* is required for the G1/S transition.²² *CDC25A* gene expression was significantly greater in PBs than in CD23⁺ aBCs, as well as the protein expression (Figure 3B). Chemical inhibition of *CDC25A* first led to a dramatic decrease in the proportion of S-phase cells and then, ultimately, to a strong reduction in the number of generated PBs (supplemental Figure 3F-G). Interestingly, PIM2 inhibition led to a decrease of *CDC25A* protein level in PBs without affecting *CDC25A* expression (Figure 3B; supplemental Figure 3H). At D4, the addition of PIMi to cycloheximide-treated cells accelerated the degradation of *CDC25A* (Figure 3C; supplemental Figure 3I), whereas in the presence of MG-132, cells maintained *CDC25A* expression (Figure 3D).

Cyclin-dependent kinase (CDK) inhibitor 1B (p27^{Kip1}, encoded by the *CDKN1B* gene) prevents progression to G1.²³ This effect is linked to the location of p27^{Kip1} in the nucleus; cells that enter the cell cycle exhibit a cyclin D2-mediated nuclear export of p27^{Kip1}.²⁴ *CDKN1B* expression was significantly higher in PBs than in CD23⁺ aBCs, whereas the p27^{Kip1} protein expression was lower and mainly located in the nucleus in CD23⁺ aBCs (Figure 3E). In addition, we detected the threonine 198-phosphorylated [p(Thr198)] form of p27^{Kip1}, predominantly expressed in PBs compared with CD23⁺ aBCs. These results prompted us to assess the half-life of p27^{Kip1} in PBs vs CD23⁺ aBCs. Cycloheximide-treated PBs were more susceptible to

Figure 3. PIM2 supports cell cycle entry by promoting the G1/S transition. (A) Flow cytometry evaluation of the cell cycle in PBs on D6 after treatment with SSO-PIM2 and increasing doses of PIMi, compared with controls (n = 6). (B) Left: *CDC25A* mRNA expression in CD23⁺ aBCs and PBs on D6. Data are presented as the median (range), n = 10. Right: *CDC25A* protein expression (in the red square) in CD23⁺ aBCs and PBs on D6 after treatment with PIMi. †Nonspecific band. (C) D4 B cells were treated with PIMi and incubated with cycloheximide (CHX). At the indicated time points, *CDC25A* expression was analyzed by immunoblotting. (D) On D4, B cells were treated with PIMi and incubated in the presence of MG-132 for 2 hours. *CDC25A* expression was analyzed by immunoblotting. (E) Left: *CDKN1B* mRNA expression in CD23⁺ aBCs and PBs on D6. Data are presented as the median (range), n = 10. Right: PIM2, p(Thr198)-p27^{Kip1} (p-p27), and total p27^{Kip1} protein expression in CD23⁺ aBCs and PBs on D6 in total protein extracts and nuclear and cytoplasmic fractions. (F) Cells were incubated with CHX on D6, just before sorting. At the indicated time points, p27^{Kip1} expression in CD23⁺ aBCs and PBs was analyzed by immunoblotting. (G) Cells were incubated for 4 hours with MG-132 before sorting on D6. p27^{Kip1} expression in CD23⁺ aBCs and PBs was assessed by immunoblotting. (H) Left: Immunoprecipitation (IP) of p27^{Kip1} in D4-activated B cells. PIM2 and p27^{Kip1} were detected by immunoblotting. Right: On D4, activated B cells were shortly treated with PIMi. At the indicated time points, p-p27 and total p27^{Kip1} protein expression were assessed by immunoblotting. (I) PIM2 and p27^{Kip1} protein expression in PBs after treatment with PIMi in total protein extracts and nuclear and cytoplasmic fractions. (J) On D6, cells were treated with PIMi and incubated with CHX before sorting. At the indicated time points, p27^{Kip1} expression in PBs was assessed by immunoblotting. (K) On D6, cells were treated with PIMi for 2 hours before sorting. p-p27 and total p27^{Kip1} were assessed by immunoblotting. (L) On D6, cells were incubated in the presence or absence of PIMi for 2 hours before the addition (or not) of MG-132 for 4 hours. Left: p27^{Kip1} was assessed by immunoblotting. Right: Polyubiquitinated p27^{Kip1} and native p27^{Kip1} were assessed by immunoblotting. (M) PIM2 promotes the G1/S transition. Positive effects (in pink) are PIM2 dependent, whereas effects not directly related to PIM2 are shown in green. On one hand, PIM2 induces p27^{Kip1} degradation once the protein is localized in the cytoplasm; on the other hand, PIM2 maintains the expression of *CDC25A*. Statistical significance was evaluated by using Kruskal-Wallis tests (panel A, for PIMi experiment) and Mann-Whitney U test (panels A [for SSO experiment], B, and E). *P < .05, **P < .01, ****P < .0001. DAPI, 4',6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; IP-Ub, immunoprecipitation of the ubiquitin forms; NT, no treatment; ns, not significant. Further details are presented in supplemental Figure 3.




Figure 4.




Figure 4. PIM2 is required to counter mitochondrial apoptosis. (A) Analysis of cell death was performed in the model previously described.⁵ Cell viability (number of caspase 3–active negative [alive cells] and positive [death cells]) and cell differentiation (number of P3 cells, P2/CD23⁺ cells, P2/CD23⁻ cells, and P1 cells) were assessed by using flow cytometry. (A, left) The total numbers of dead cells and living cells in the 4 populations on D6. The pie chart shows the percentage of cells, n = 7. (A, right) On D4, cells were treated (or not) with QVD-OPH. On D6, the numbers of cells in each population were recorded. Data are presented as the mean ± SD, n = 6. (B) CASP3 mRNA expression in the various cell populations on D6. The data are presented as the median (range), n = 6. (C) Factors in the mitochondrial apoptosis pathway involved in B-cell differentiation. The green “+” symbol represents a death-activating effect, and the red “-” symbol represents a death-inhibiting effect. The pro-apoptotic protein BAD causes depolarization of the mitochondria, followed by the cleavage of procaspase 9 into active caspase 9, which in turn cleaves procaspase 3 to generate an intermediate, inactive p20 form. Following an auto-catalytic process, the p20 form gives rise to catalytically active p19 and p17 fragments. These molecules cleave PARP (the end effector in the apoptotic process) and also p20 in a feedback loop. Molecules are released from the mitochondria after depolarization

p27^{Kip1} proteasome-mediated degradation, as shown after the addition of MG-132 (Figure 3F-G). Interestingly, in highly proliferative D4 B cells, endogenous immunoprecipitation of p27^{Kip1} revealed the binding of PIM2, and short treatment by PIMi resulted in a time-dependent decrease of p(Thr198)-p27^{Kip1} (Figure 3H). PBs generated after PIM2 inhibition showed an increase in the global level of p27^{Kip1} expression, independently to *CDKN1B* expression, particularly in the nucleus (Figure 3I; supplemental Figure 3J-K). In cycloheximide-treated PBs, the addition of PIMi stabilized p27^{Kip1} (Figure 3J; supplemental Figure 3L). Finally, PIMi-treated PBs showed a decrease of p(Thr198)-p27^{Kip1} as well as a decrease in poly-ubiquitinated forms of p27^{Kip1} in the presence of MG-132 (Figure 3K-L; supplemental Figure 3M).

Overall, PIM2 expression during PB differentiation promotes the G1/S transition in prePBs by stabilizing CDC25A phosphatase and increasing the degradation of cytoplasmic p27^{Kip1} (Figure 3M).

PIM2 hinders the execution of caspase 3-driven apoptosis

The most prominent changes during PB commitment are related to cell death/survival.⁴ Indeed, in culture, the majority of B cells were dead on D6 (Figure 4A). The pan-caspase inhibitor QVD-OPH rescued the cells from death with the exception of the PBs; the latter seemed to be protected from apoptosis and despite an increase in *CASP3* gene expression (Figure 4A-B). Investigations of the proteins produced by the various cell subsets in our differentiation model showed that PBs contained higher levels of anti-apoptotic phosphorylated BAD (pBAD) and X-linked inhibitor of apoptosis protein (XIAP) (Figure 4C-D).^{9,10} Consistent with this finding, immunoprecipitation of PIM2 revealed a binding on BAD most likely required before phosphorylation (Figure 4E). In accordance with this finding and despite the elevation in levels of procaspase 3, PBs displayed low levels of caspase 3 autocatalytic activity and thus did not produce many active p19/p17 forms [as highlighted by lower levels of cleaved poly(ADP-ribose) polymerase (PARP)] as P2/CD23⁺ cells did (Figure 4F).²⁵ Overall, PBs maintain caspase 9 in an inactivated state, and XIAP protein remains protected from degradation (Figure 4C-F).²⁶ XIAP is thought to have a key role in PBs by inhibiting caspase 3 activation. Indeed, immunoprecipitation of caspase 3 and XIAP revealed the binding of XIAP on p19/p17 fragments of caspase 3 (Figure 4G), which impairs their catalytic activity on procaspase 3.^{27,28} Lastly, the P2/CD23⁺ cells' complete degradation of PARP (Figure 4F) showed that terminal B-cell differentiation is associated with apoptosis if cells are not otherwise protected by the PB commitment. In PBs, PIM2 inhibition induced an increase in activated caspase 3 levels and thus a decrease in cell viability (Figure 4H-I; supplemental Figure 4A). This effect was driven by: (1) the strong mitochondrial depolarization due to the inhibition of

pBAD; (2) the production of cleaved caspase 9; (3) the decrease in XIAP; (4) the detection of the p17 fragment of caspase 3; and (5) PARP cleavage (Figure 4J-L). Lastly, addition of the caspase 3 inhibitor Q-DEVD-OPH rescued the PBs from cell death (supplemental Figure 4B).

Taken as a whole, these data show that PIM2 counteracts the activation of caspase 3 in PBs and thus promotes cell survival.

PIM2 stabilizes cytoplasmic p21^{Cip1} and promotes the latter's binding to caspase 3

As with p27^{Kip1}, nuclear p21^{Cip1} is a CDK inhibitor and inhibits entry into the S phase of the cell cycle.²⁹ PB commitment was associated with a significant increase in transcription of *CDKN1A* (which encodes p21^{Cip1}), and levels of p21^{Cip1} were markedly higher in PBs than in CD23⁺ aBCs (Figure 5A). Surprisingly, p21^{Cip1} was essentially expressed in the cytoplasm, and endogenous immunoprecipitation experiments yielded a multiprotein complex in which p21^{Cip1} interacted with PIM2 and heat shock protein 90β (HSP90β) (Figure 5B-C). Moreover, PIM2 inhibition led to a dramatic decrease in cytoplasmic p21^{Cip1} without effect on either *CDKN1A* expression or nucleus relocalization (Figure 5D; supplemental Figure 5A-B). The addition of PIMi to cycloheximide-treated cells accelerated the degradation of p21^{Cip1} (Figure 5E). Treatment with MG-132 induced a strong accumulation of p21^{Cip1}, and the addition of PIMi was associated with elevated poly-ubiquitinated p21^{Cip1} (Figure 5F-G). XG21 cells presented similar results (supplemental Figure 5C-F). Collectively, these results show that PIM2 stabilizes p21^{Cip1} in PBs by promoting its binding to a cytoplasmic multiprotein complex and, thus, preventing proteasome-mediated degradation of p21^{Cip1}.

This PIM2-induced cytoplasmic stabilization of p21^{Cip1} prompted us to question the latter's role in PB commitment. As described previously for other cell types,^{30,31} we hypothesized that p21^{Cip1} interacts with procaspase 3. In fluorescence resonance energy transfer (FRET)³² experiments on XG21 cells, we detected a p21^{Cip1}/procaspase 3 complex whose formation was abrogated by pretreatment of the cells with PIMi (Figure 5H). Immunoprecipitation experiments confirmed the presence of this complex in PBs (Figure 5I; supplemental Figure 5G). To determine whether p21^{Cip1} mediates apoptosis inhibition, small interfering RNA was used to downregulate *CDKN1A* expression (supplemental Figure 5H). On D6, the generated PBs were found to contain p17-forms of caspase 3 and cleaved PARP, confirming that apoptosis had taken place (Figure 5J; supplemental Figure 5I). Treatment with the small-molecule p21^{Cip1} inhibitor UC2288 was associated with a dose-dependent decrease in cell viability, which was restored by treatment with the caspase 3 inhibitor Q-DEVD-OPH (Figure 5K; supplemental Figure 5J-K).

Figure 4 (continued) and block the action of the inhibitor of apoptosis proteins, including XIAP. The phosphorylation of BAD leads to its cytoplasmic sequestration by 14-3-3, thus hijacking its pro-apoptotic effect. (D and F) Assessment of the protein expression of factors involved in the mitochondrial apoptosis pathway during primary B-cell differentiation. (E) Immunoprecipitation of PIM2 in PBs. PIM2 and BAD were detected by immunoblotting. (G) Immunoprecipitation (IP) of XIAP (top) and caspase 3 (bottom) in PBs. XIAP and caspase 3 were detected by immunoblotting. (H-I) Flow cytometry evaluation of the percentage of active caspase 3-positive PBs on D6, after treatment with SSO-PIM2 (H) or with increasing doses of PIMi (I), relative to controls. Data are presented as the mean ± SD, n = 8. (J) One representative result of the tetramethylrhodamine methyl ester (TMRM) signal on D6 in PBs (analyzed by flow cytometry) after treatment with SSO-PIM2 (left) or PIMi (right), compared with controls. (K-L) Assessment of protein expression levels in PBs on D6 for factors involved in the mitochondrial apoptosis pathway after PIM2 inhibition by SSO-PIM2 (K) or PIMi (10 μM) (L), compared with controls. Statistical significance was evaluated by using Mann-Whitney U (panels A and B), Wilcoxon (panel H), and Friedman (panel I) tests. *P < .05, **P < .01, ***P < .001, ****P < .0001. CI, cleaved; DMSO, dimethyl sulfoxide; FSC, forward scatter; NBC, naive B cells; ns, not significant; NT, no treatment. Further details are presented in supplemental Figure 4.




Figure 5.




Figure 5. PIM2 helps to stabilize cytoplasmic p21^{Cip1} and promotes the caspase 3/p21^{Cip1} interaction. (A) Left: *CDKN1A* mRNA expression was measured on D6 in CD23⁺ aBCs and PBs. Data are presented as the median (range), n = 10. Right: PIM2 and p21^{Cip1} protein expression on D6 in CD23⁺ aBCs and PBs. (B) PIM2 and p21^{Cip1} protein expression was measured in nuclear and cytoplasmic fractions from CD23⁺ aBCs and PBs. (C) PIM2 (left) and p21^{Cip1} (right) immunoprecipitation (IP) in PBs. Heat shock protein 90β (HSP90β), p21^{Cip1}, and PIM2 were detected by immunoblotting. (D) PIM2 and p21^{Cip1} protein expression after treatment with SSO-PIM2 (top) or PIMi (bottom) in total extracts from PBs. (E) PBs were sorted and then treated with PIMi and incubated with cycloheximide (CHX). At indicated times, p21^{Cip1} expression was assessed by immunoblotting. (F) PBs were sorted and then treated with PIMi for 2 hours in the presence (or not) of MG-132. p21^{Cip1} was assessed by immunoblotting. (G) PBs were treated for 30 minutes with PIMi after incubation in the presence of MG-132 for 2 hours. Polyubiquitinated p21^{Cip1} and native p21^{Cip1} were assessed by immunoblotting. (H) FRET/FLIM (Förster resonance energy transfer (FRET) by fluorescence lifetime imaging (FLIM)) was analyzed in XG21 cells stained for caspase 3 (the donor) in the presence or absence of p21^{Cip1} (the acceptor). Cells were left untreated (upper panels) or treated with PIMi (lower panels). The graph shows the quantified ΔLifetime. Data are presented as the median (range), n = 20 cells per condition. Pseudocolor scale, pixel-by-pixel ΔLifetime. Scale bar: 10 μm. (I) p21^{Cip1} (top) and caspase 3 (bottom) IP in PBs. Caspase 3 and p21^{Cip1} were detected by immunoblotting. (J) p21^{Cip1}, procaspase 3, cleaved caspase 3, and cleaved PARP protein expression on D6 in PBs, after transfection with siCDKN1A or siCTL on D4. (K) On D4, activated B cells were treated for 24 hours with increased doses of p21i in the presence or absence of Q-DEVD-OPH. PB viability (the proportion of active caspase 3–negative cells) was assessed by flow cytometry. Data are presented as the mean ± SD, n = 5. (L) The PIM2/p21^{Cip1}/caspase 3 pathway in PBs. p21^{Cip1} is stabilized in the cytoplasm by a protein complex that also includes PIM2 and HSP90β. Due to this localization, p21^{Cip1} interacts with procaspase 3 and blocks its activation. Statistical significance was evaluated by using Mann-Whitney U (panels A and H) and Kruskal-Wallis (panel K) tests. *P < .05, ***P < .001, ****P < .0001. CI, cleaved; DMSO, dimethyl sulfoxide; IgG, immunoglobulin G; IP-Ub, immunoprecipitation of ubiquitin forms; ns, not significant; NT, no treatment; siCTL, small interference (si) RNA control (CTL). Further details are presented in supplemental Figure 5.

Taken as a whole, these findings show that in addition to its mitochondrial effects, PIM2 inhibits the execution of apoptosis by stabilizing cytoplasmic p21^{Cip1}, allowing the latter to bind to procaspase 3, and thus inhibiting the production of activated caspase 3 (Figure 5L).

Mature PCs need PIM2 to inhibit the activation of caspase 3

PC maturation is a continuum that runs from PBs to fully mature, long-lived PCs such as those residing in the bone marrow (BM) niche, in which cell survival depends on various extrinsic factors.³³ A comparison of various tonsil-derived B-cell populations,

PBs, and BM PCs revealed that the level of *PIM2* expression increased along the maturation pathway (Figure 6A). On paraffin-embedded BM biopsy specimens, staining experiments revealed that virtually all BM PCs (detected either with CD138 or B-cell maturation antigen markers) were strongly positive for PIM2 (Figure 6B; supplemental Figure 6A-B).

To characterize the regulation and functional contribution of PIM2 in mature PCs, we adapted our cell culture model so that it produced nonproliferating CD138⁺ PCs (supplemental Figure 6C-F), in line with reports on an early PC (ePC) phenotype.^{34,35} As was the case in BM PCs, high levels of PIM2 mRNA and




Figure 6.




Figure 6. PIM2 in BM plasma cells. (A) *PIM2* mRNA expression in different tonsil-derived B-cell populations ($n = 7$) and in BM PCs ($n = 9$). The data are presented as the median (range). (B) Immunofluorescence staining of PIM2 (green) and CD138 (orange) on paraffin-embedded normal BM. 4',6-Diamidino-2-phenylindole (blue) stains the nucleus. Scale bar: 20 μm . (C) *PIM2* mRNA and PIM2 protein expression in CD23⁺ aBCs and PBs on D6 and ePCs on day 10 (D10). Data are presented as the median (range), $n = 10$. (D) On D10, ePCs were sorted, starved, and treated (or not) with an anti-IL6R monoclonal antibody 1 hour before stimulation. IL-6 and supernatants of BM mesenchymal stroma cells (s-MSC) were pre-incubated (or not) for 1 hour with an anti-IL6 monoclonal antibody. *PIM2* mRNA expression (left) and protein expression (right) in ePCs 5 hours after the addition of IL-6 or s-MSC. Data are presented as the mean \pm SD, $n = 4$. (E) Immunofluorescence staining of PIM2 (green), CD41 (red), and CD138 (orange) on paraffin-embedded normal BM. 4',6-Diamidino-2-phenylindole (blue) stains the nucleus. Scale bar: 20 μm . (F) On day 9, cells were treated with PIMi. The proportion of active caspase-3-positive cells was assessed on D10 by using flow cytometry. Data are presented as the mean \pm SD, $n = 6$. (G) On D10, live cells were treated for 2 hours with PIMi. Protein expression levels of caspase 9, XIAP, caspase 3, and p21^{Cip1} were assessed by immunoblotting. (H) p21^{Cip1} expression was assessed on D10 in nuclear and cytoplasmic fractions by immunoblotting and immunofluorescence. Sytox (blue) stains the nucleus. Scale bar: 5 μm . (I) FRET/FLIM data were analyzed for ePCs stained for (the donor) PIM2 (left) or caspase 3 (right) in the presence or absence of p21^{Cip1} (the acceptor). The graph shows the quantified Δ Lifetime. Data are presented as the median (range). Pseudocolor scale, pixel-by-pixel Δ Lifetime. Scale bar: 10 μm . Statistical significance was evaluated by using the Mann-Whitney *U* test in panels A, C, D, F, and I. * $P < .05$, ** $P < .01$, *** $P < .001$, **** $P < .0001$. DMSO, dimethyl sulfoxide; FRET/FLIM, Förster resonance energy transfer (FRET) by fluorescence lifetime imaging (FLIM); FSC, forward scatter; GC, germinal center; MBC, memory B cells; NBC, naive B cells; ns, not significant; NT, no treatment. Further details are presented in supplemental Figure 6.

protein expression were observed in ePCs (Figure 6C). This expression was driven by IL-6 via STAT3 signaling and by the supernatant from a mesenchymal stromal cell culture (Figure 6D). As expected, the addition of anti-IL-6 and anti-IL-6 receptor antibodies to the cell culture prevented the induction of PIM2. In this context, we observed clusters of CD138⁺/PIM2⁺ PCs in some areas on BM biopsy specimens, close to CD41⁺ megakaryocytes, cells known to produce large amounts of IL-6 and participating in PC BM niche (Figure 6E).³³

Treatment of ePCs with PIMi induced an elevation of activated caspase 3 levels, and immunoblot experiments confirmed the increase in mitochondrial depolarization and the execution of apoptosis (Figure 6F-G). PIMi treatment also led to a significant decrease in p21^{Cip1} levels (Figure 6G). Interestingly, ePCs (as in some BM PCs) only expressed p21^{Cip1} in the cytoplasm (Figure 6H; supplemental Figure 6G), and FRET experiments revealed that PIM2 interacted with p21^{Cip1} as well as p21^{Cip1} with caspase 3 (Figure 6I).

Taken as a whole, our data show that PIM2 is still required in quiescent PCs to protect cells from caspase 3 activation; PIM2 acts at various levels and notably stabilizes cytoplasmic p21^{Cip1}.

BH3 mimetics and PIM2 inhibitors have synergistic effects in MM

Although the involvement of PIM2 in MM has been recognized for more than a decade, our present findings prompted us to further investigate the status of PIM2 in malignant PCs. Data from the DepMap Project showed that mRNA expression of *PIM2* (but not of *PIM1*) was elevated in MM cells compared with other tumor cells, whereas CRISPR screening revealed a specific high PIM2 dependency score for malignant PCs (Figure 7A-B;

supplemental Figure 7A). BM biopsy results from patients with MM revealed intense, widespread expression of PIM2 (Figure 7C). Data from the University of Arkansas Total Therapy 2 (TT2) MM cohort showed the strongest *PIM2* expression levels in the high-risk molecular subgroups (supplemental Figure 7B).³⁶ An analysis of data from 765 patients in the multiple myeloma research foundation CoMMpass Study cohort showed that *PIM2* expression was significantly elevated in high-risk cytogenetic subgroups and low in low-risk subgroups (supplemental Figure 7C).^{37,38} In addition, high PIM2 expression patients compared with the PIM2^{low} group had a worse survival probability (Figure 7D). This is in line with small conditional RNA-seq data on malignant PCs from patients resistant to the carfilzomib-daratumumab combination therapy, which presented higher *PIM2* expression (supplemental Figure 7D).³⁹ Likewise, we observed a significant increase in *PIM2* expression in cells from an in-house cohort of 14 patients with disease progression soon after first-line treatment (supplemental Figure 7E). Collectively, these data suggest that the severity of MM is associated with PIM2 expression levels.

Drug resistance is the greatest challenge in MM. It might be possible to overcome this obstacle by acting at the mitochondrial level and lowering the threshold for triggering mitochondrial apoptosis.⁴⁰ Venetoclax is reportedly effective in BCL2-translocated MM patients.⁴¹ Furthermore, myeloid cell leukemia-1 (MCL1) is also an attractive target in MM^{41,42} because of its essential effects on PC survival via inactivation of the pro-apoptotic multidomain of BAX and BAK effectors.⁴³ However, in contrast to BCL2 and BCL-xL, MCL1 activity is not antagonized by BAD.⁴⁴ Interestingly, data from the TT2 MM cohort showed that the expression levels of MCL1 and PIM2 are significantly correlated (supplemental Figure 7F). We hypothesized that targeting both PIM2 and MCL1 might have synergistic




Figure 7. Reconsideration of PIM2 as an effective target in MM. (A) PIM2 gene expression in cell lines derived from various solid and blood cancers (<https://depmap.org/portal/>). (B) CRISPR screening data from the DepMap Project show that PIM2 presents the highest dependency score for the 20 tested MM cell lines, relative to other cell lines. (C) Immunohistofluorescence staining of PIM2 (green) and CD138 (orange) in paraffin-embedded BM from patients with MM. 4',6-diamidino-2-phenylindole (blue) stains the nucleus. Scale bars: 20 μm (top); 50 μm (bottom). (D) Overall survival of patients from the CoMMpass cohort as a function of PIM2 expression (PIM-high group, $n = 539$; PIM-low group, $n = 227$). The expression cutoff was determined by applying the MaxStat package (cutoff = 313.02). (E) Effects of BH3 mimetics and PIMi on apoptosis. BH3 mimetics (eg, MCL1i, venetoclax) inhibit the binding of antiapoptotic molecules (MCL1 and BCL2, respectively) to the




Figure 7. (continued) pro-apoptotic effectors BAK and BAX; this leads to mitochondrial depolarization and, ultimately, cell apoptosis PIMi enhances the action of BAD: BAD binds to BCL2 and BCL-XL and therefore acts independently of MCL1i. The combination of these 2 compounds might result in greater activation of BAX and BAK and may increase the likelihood of cell death. (F-G) Left: The results of a cell viability assay and a synergy analysis after treatment with increasing concentrations of AZD1208 (PIMi) and AZD5991 (MCL1i) in XG7 cells (F) and U266 cells (G). Right: Flow cytometry assessment of apoptosis using 4',6-diamidino-2-phenylindole (DAPI)/CaspGlow staining and immunoblotting for the detection of caspase 3 and PARP cleavage, after treatment of XG7 cells (panel F) and U266 cells (panel G) with selected doses of inhibitors. The bar plot shows the percentage of caspase 3-active positive cells. Data are presented as the mean \pm SD, $n = 5$. (H) Flow cytometry assessment of viability for primary cells from 6 patients with MM. The bar plot shows the percentage of viable CD138⁺ MM cells and CD138⁻ cells, relative to a control (set to 100%) after treatment with the selected doses of inhibitor. Statistical significance was evaluated by using the Mann-Whitney U test in panels F, G, and H. ** $P < .01$. See also supplemental Figure 7.

effects on mitochondria depolarization because the 2 proteins act at different levels (Figure 7E). To this end, we first evaluated the respective effects of PIMi,⁴⁵ an MCL1 inhibitor (AZD5991,

referred to hereafter as MCL1i)⁴⁶ alone and then when combined. The XG7 and RPMI8226 cell lines were sensitive to MCL1i but the U266 cells were not (supplemental Figure 7G).




Figure 7. (Continued).

Low-dose treatment with PIMi greatly enhanced the response to MCL1i in XG7 and RPMI8226 cells (Figure 7F; supplemental Figure 7H). Interestingly, U266 cells (resistant to PIMi alone and MCL1i alone) became sensitive when the drugs were combined (Figure 7G). Lastly, PIMi and MCL1i had synergistic effects on primary MM cells from 6 patients without effect on CD138⁻ cells (Figure 7H).

Taken as a whole, these results confirmed that the mitochondrial control of PIM2 is similar in normal and malignant PCs; this finding opens up novel treatment options in MM.

Discussion

The processes by which committed B cells and nascent PBs switch from one molecular program to another had not previously been fully characterized. Here, our experiments with human primary B cells showed that PIM2 kinase is a pivotal factor for the generation and maintenance of PB and PC populations. In particular, our results show how committed B cells reenter the cell cycle after their proliferation burst and, under subsequently restricted culture conditions, express high levels of PIM2 and thus decrease mitochondrial apoptosis.

Our molecular characterization provided strong evidence of the regulation of *PIM2* gene expression and illustrates the status of *PIM2* as a true PC-identity gene recruited at the same time as *PRDM1* and *IRF4*, once *BACH2* repression has been released. In prePBs and PBs, both IL-10 and IL-21 cytokines drive *PIM2* expression via pSTAT3 signaling and (in PCs) by IL-6, which establishes a direct link between growth factor-induced transcription and a kinase-dependent pathway that promotes survival and cell cycle reentry.

The cell cycle provides windows of opportunity for chromatin remodeling and thus gene activation.⁴⁷ Committed B cells increase their expression of *CDC25A*, and in parallel *PIM2* helps to stabilize the *CDC25A* protein and thus prompts cells to enter the S phase and progress to the PB state independently of effects on apoptosis.²² Interestingly, promotion of the cell cycle by *PIM2* is accentuated by the degradation of cytoplasmic p27^{Kip1}, which prevents the latter from accumulating or returning to the nucleus. Indeed, the effect of *PIM2* on p27^{Kip1} is mediated by the phosphorylation of threonine 198 residue, consistent with the known cytoplasmic localization of p(Thr198)-p27^{Kip1} and its binding to 14-3-3 leading to its proteasomal degradation.⁴⁸ In contrast, in PCs, p27^{Kip1} accumulated in the nucleus, independently of high *PIM2* expression, to halt the cell cycle and so without being degraded by cytoplasmic *PIM2*.

Caspases 9 and 3 become resistant to activation by apoptotic stimuli when B cells differentiate into PBs, and the apoptosis of short-lived PCs in vitro and in vivo is largely independent of the key apoptotic caspases.⁴⁹ Our present results provide insights into the mechanisms whereby B-cell death is avoided, despite intense expression of cell death-related genes in committed cells,⁴ allowing PB generation and survival. Production of pBAD helps to maintain the integrity of mitochondria, as evidenced by increased XIAP expression and the overall inhibition of caspase 3 self-activation. Knockdown and dose-dependent experiments have shown that this mitochondrial adaptation is mediated and made possible by high levels of *PIM2* expression and its binding activity to BAD; this is in line with data from constitutive *PIM2* expression models, with the detection of pBAD, its binding to 14-3-3, and inhibition of BAD/BCL-XL binding.^{10,50}

One of the ways in which *PIM2* regulates apoptosis during the differentiation of B cells into PBs involves restricting p21^{Cip1} to the cytoplasm. During this step, cells progress from G1 to S and proliferate; hence, the cytoplasmic expression of p21^{Cip1} makes sense because its presence in the nucleus blocks cells in G1.⁵¹ However, further investigations on quiescent PC populations show that p21^{Cip1} stays in the cytoplasm, which sheds light on its pleiotropic functions. In PBs, *PIM2* stabilizes cytoplasmic p21^{Cip1} by promoting the formation of a complex with heat shock protein 90 β and thus reducing the proteasomal degradation of p21^{Cip1}. Interestingly, p21^{Cip1} also binds to procaspase 3 in a *PIM2*-dependent manner, and FRET experiments showed that the addition of PIMI abrogated binding of p21^{Cip1} to procaspase 3. In PBs, *PIM2* acts by promoting the formation of a multiprotein complex, which inhibits the caspase 3 activation. This effect complements the production of pBAD and the inhibition of mitochondrial depolarization and shows that *PIM2* acts in several ways to ensure the survival of PBs.

Entry into cell cycle quiescence accompanies the final phenotypic maturation of PCs and requires CDK inhibitors regulated by IL-6.⁵² By modifying the culture conditions, we obtained fully mature PCs that strongly expressed *PIM2* and absolutely required IL-6. At the cellular level, the antiapoptotic effects of *PIM2* were characterized by maintenance of mitochondrial integrity and promotion of caspase 3/p21^{Cip1} binding. Although it is now accepted that viability is not an intrinsic property of BM PCs but is conferred on the cells by their immediate environment,⁵³ our present observations of marked expression of *PIM2* in BM PCs suggest that this kinase has a crucial role in long-term cell survival and might be involved in the functional activity of the PC niche through IL-6-dependent crosstalk between the cell and its microenvironment.⁵⁴

Our results revealed a hitherto unexpected role of *PIM2* kinase in terminal B-cell differentiation and, more generally, the biology of the PCs. The pleiotropic effects of *PIM2* kinase enable the cell to modify its regulation of apoptosis and to promote survival when faced with protein secretion overload. The data from the DepMap Project show that malignant PCs are “addicted” to *PIM2*, and elevated *PIM2* expression in the most severe cases of MM suggests that *PIM2* is linked to clinical severity. Small-molecule inhibitors of PIM have produced some encouraging results in preclinical models and recently in MM patients with relapsed and/or refractory disease.⁵⁵ Indeed, and despite a relative low objective response rate (partial response or better), in patients who reached the recommended dose of treatment, PIM447 drug exhibited single-agent antitumor activity with a significant improvement of the median progression-free survival and the rate of clinical benefit. However, BM examination of patients failed to reveal a clinically significant reduction in malignant PCs, suggesting that PIM447 exerted antitumor responses via cytostatic rather than apoptotic mechanisms.⁵⁵ Taking into account that MM tumor cells increase their dependence on MCL1 during the course of the disease,⁴¹ we could speculate that MCL1 could counteract the induction of cell death by PIMI. In the context of the PIM447 clinical trial,⁵⁵ antiproliferative effects could appear at low doses, whereas cell death would require dose escalation, possibly with unacceptable toxicities, to counterbalance MCL1 dependency. Given that the action of MCL1 on the mitochondrial membrane is independent of BAD, dual pharmacologic inhibition of *PIM2* and MCL1 is highly synergistic; low doses of PIMI significantly increased the efficacy of the anti-MCL1 drug. Interestingly, this drug combination can reverse the primary resistance of U266 cells to MCL1i and PIMI.

In conclusion, our present results showed that the final transcriptional modifications in B cells committed to differentiation into PBs are associated with the expression of a set of crucial genes, including *PIM2*. The newly established adaptive status of the generated PBs is maintained in mature PCs. Lastly, we showed that the antiapoptotic effects *PIM2* kinase should be further investigated in the context of novel treatment strategies in MM.

Acknowledgments

Cell sorting was performed at the Biosit Flow Cytometry and the CytomeTRI cell-sorting facilities (UMS6480 Biosit). The authors are indebted to the Centre de Ressources Biologiques-Santé (BB-0033-00056; <http://www.crbsante-rennes.com>) at Rennes University Medical Center for its help with processing biological samples, and they also thank several clinicians and patients for providing samples for

research purposes. The authors thank the MMRF (Multiple Myeloma Research Foundation) for sharing biological and clinical data for patients enrolled in the CoMMpass study via the MMRF genomics portal.

M.H. has received a doctoral fellowship from FHU CAMIn, Ligue Contre le Cancer/Comité d'Île et Vilaine. A.P. received a fellowship from Région Bretagne and Ligue Nationale contre le Cancer. Immunofluorescence studies were performed at the Microscopy Rennes imaging center (MRic) and in the H2P2 facility, both of which are members of the UMS 6480 Biosit and the French national France-Biomedicine infrastructure network funded by the French Research Agency (ANR-10-INBS-04). Funding support for this article was provided by the an internal grant from the Hematology Laboratory, university hospital of Rennes, and la Ligue contre le Cancer Région Grand Ouest.

Authorship

Contribution: M.H. designed and conducted the experiments and wrote the paper; G.C. designed the cell differentiation model and performed cytometry and cell sorting; F.C. performed genomic analysis; E.A. performed chromatin immunoprecipitation–quantitative PCR STAT3 experiments; J.D. performed drug combination experiments; A.P. performed single-cell quantitative PCRs; C.D. helped with BACH2 assays and discussed results; S.M. performed CDC25A immunoblotting; G.B. performed FRET experiments; R.V. performed immunostaining; F.L.-G. provided BM biopsy specimens; A.M. designed morpholino SSO; O.D. provided MM samples; K.T. discussed results; L.D. provided the antisense strategy; J.M. provided cell lines and original data; and T.F. designed and supervised the experiments and wrote the paper.

Conflict-of-interest disclosure: M.H., G.C., A.M., L.D., J.M., and T.F. have applied for a European patent on the use of an SSO to modulate PIM2 expression. The remaining authors declare no competing financial interests.

ORCID profiles: G.C., 0000-0001-9126-3313; F.C., 0000-0003-3639-6775; J.D., 0000-0001-8929-6992; C.D., 0000-0003-1510-6484; G.B., 0000-0002-7359-5733; A.P., 0000-0001-8179-433X; A.M., 0000-0002-3042-8206; K.T., 0000-0002-6809-917X; L.D., 0000-0002-9480-8515; J.M., 0000-0002-5717-3207; T.F., 0000-0002-6437-4189.

Correspondence: Thierry Fest, INSERM U1236, Faculté de Médecine, 2 avenue du Pr Léon Bernard, CS 34317, 35043 Rennes Cedex, France; e-mail: thierry.fest@univ-rennes1.fr.

Footnotes

Submitted 7 September 2021; accepted 14 January 2022; prepublished online on *Blood* First Edition 2 February 2022. DOI 10.1182/blood.2021014011.

Raw data are accessible in the Gene Expression Omnibus database (accession number GSE136990).

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

REFERENCES

1. Fairfax KA, Kallies A, Nutt SL, Tarlinton DM. Plasma cell development: from B-cell subsets to long-term survival niches. *Semin Immunol*. 2008;20(1):49-58.
2. Willis SN, Nutt SL. New players in the gene regulatory network controlling late B cell differentiation. *Curr Opin Immunol*. 2019;58:68-74.
3. Shaffer AL III, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. *Annu Rev Immunol*. 2012;30(1):565-610.
4. Caron G, Hussein M, Kulis M, et al. Cell-cycle-dependent reconfiguration of the DNA methylome during terminal differentiation of human B cells into plasma cells. *Cell Rep*. 2015;13(5):1059-1071.
5. Pignarre A, Chatonnet F, Caron G, Haas M, Desmots F, Fest T. Plasmablasts derive from CD23-activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction. *Blood*. 2021;137(9):1166-1180.
6. Mondello P, Cuzzocrea S, Mian M. Pim kinases in hematological malignancies: where are we now and where are we going? *J Hematol Oncol*. 2014;7(1):95-103.
7. Keane NA, Reidy M, Natoni A, Raab MS, O'Dwyer M. Targeting the Pim kinases in multiple myeloma. *Blood Cancer J*. 2015;5(7):e325.
8. Panchal NK, Sabina EP. A serine/threonine protein PIM kinase as a biomarker of cancer and a target for anti-tumor therapy. *Life Sci*. 2020;255:117866.
9. Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. *Genes Dev*. 2003;17(15):1841-1854.
10. Yan B, Zemskova M, Holder S, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. *J Biol Chem*. 2003;278(46):45358-45367.
11. Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. *Haematologica*. 2011;96(4):574-582.
12. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. *Pharmacol Rev*. 1995;47(2):331-385.
13. Combès E, Andrade AF, Tosi D, et al. Inhibition of ataxia-telangiectasia mutated and RAD3-related (*ATR*) overcomes oxaliplatin resistance and promotes antitumor immunity in colorectal cancer. *Cancer Res*. 2019;79(11):2933-2946.
14. Le Gallou S, Caron G, Delaloy C, Rossille D, Tarte K, Fest T. IL-2 requirement for human plasma cell generation: coupling differentiation and proliferation by enhancing MAPK-ERK signaling. *J Immunol*. 2012;189(1):161-173.
15. Andersson R, Gebhard C, Miguel-Escalada I, et al. An atlas of active enhancers across human cell types and tissues. *Nature*. 2014;507(7493):455-461.
16. Hnisz D, Abraham BJ, Lee TI, et al. Super-enhancers in the control of cell identity and disease. *Cell*. 2013;155(4):934-947.
17. Hipp N, Symington H, Pastoret C, et al. IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression. *Nat Commun*. 2017;8(1):1443.
18. Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. *J Immunol*. 2004;173(9):5361-5371.
19. Doody GM, Care MA, Burgoyne NJ, et al. An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. *Nucleic Acids Res*. 2010;38(16):5336-5350.
20. Shaffer AL, Lin K-I, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. *Immunity*. 2002;17(1):51-62.
21. Minnich M, Tagoh H, Bönelt P, et al. Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation. *Nat Immunol*. 2016;17(3):331-343.
22. Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. *EMBO J*. 1994;13(18):4302-4310.
23. Abbastabar M, Kheyrollah M, Azizian K, et al. Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: a double-edged sword protein. *DNA Repair (Amst)*. 2018;69:63-72.
24. Susaki E, Nakayama K, Nakayama KI. Cyclin D2 translocates p27 out of the nucleus and promotes its degradation at the G0-G1 transition. *Mol Cell Biol*. 2007;27(13):4626-4640.

25. Ponder KG, Boise LH. The prodomain of caspase-3 regulates its own removal and caspase activation. *Cell Death Discov.* 2019; 5(1):56-66.
26. Datta SR, Ranger AM, Lin MZ, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. *Dev Cell.* 2002;3(5):631-643.
27. Riedl SJ, Rensatus M, Schwarzenbacher R, et al. Structural basis for the inhibition of caspase-3 by XIAP. *Cell.* 2001;104(5):791-800.
28. Suzuki Y, Nakabayashi Y, Nakata K, Reed JC, Takahashi R. X-linked inhibitor of apoptosis protein (XIAP) inhibits caspase-3 and -7 in distinct modes. *J Biol Chem.* 2001;276(29):27058-27063.
29. Elledge SJ, Hardy CFJ, Pautz A, et al. Cell cycle checkpoints: preventing an identity crisis. *Science.* 1996;274(5293):1664-1672.
30. Asada M, Yamada T, Ichijo H, et al. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. *EMBO J.* 1999;18(5):1223-1234.
31. Suzuki A, Kawano H, Hayashida M, Hayasaki Y, Tsutomi Y, Akahane K. Procaspase 3/p21 complex formation to resist fas-mediated cell death is initiated as a result of the phosphorylation of p21 by protein kinase A. *Cell Death Differ.* 2000;7(8):721-728.
32. Bertolin G, Sizaire F, Déméautis C, et al. Optimized FRET pairs and quantification approaches to detect the activation of aurora kinase A at mitosis. *ACS Sens.* 2019; 4(8):2018-2027.
33. Winter O, Moser K, Mohr E, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. *Blood.* 2010;116(11):1867-1875.
34. Kassambara A, Rème T, Jourdan M, et al. GenomicScape: an easy-to-use web tool for gene expression data analysis. Application to investigate the molecular events in the differentiation of B cells into plasma cells. *PLOS Comput Biol.* 2015;11(1):e1004077.
35. Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. *Nat Rev Immunol.* 2015;15(3):160-171.
36. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. *Blood.* 2006;108(6):2020-2028.
37. Bergsagel PL, Mateos M-V, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. *Blood.* 2013; 121(6):884-892.
38. Perrot A, Lauwers-Cances V, Tournay E, et al. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. *J Clin Oncol.* 2019;37(19):1657-1665.
39. Cohen YC, Zada M, Wang S-Y, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. *Nat Med.* 2021;27(3):491-503.
40. Giménez-Bonafé P, Tortosa A, Pérez-Tomás R. Overcoming drug resistance by enhancing apoptosis of tumor cells. *Curr Cancer Drug Targets.* 2009;9(3):320-340.
41. Gomez-Bougie P, Maiga S, Tessoulin B, et al. BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment. *Blood.* 2018;132(25):2656-2669.
42. Slomp A, Moesbergen LM, Gong JN, et al. Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. *Blood Adv.* 2019;3(24):4202-4214.
43. Peperzak V, Vikström I, Walker J, et al. Mcl-1 is essential for the survival of plasma cells [published correction appears in *Nat Immunol.* 2013;14(8):877]. *Nat Immunol.* 2013;14(3):290-297.
44. Wei AH, Roberts AW, Spencer A, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. *Blood Rev.* 2020;44:100672.
45. Keeton EK, McEachern K, Dillman KS, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. *Blood.* 2014;123(6):905-913.
46. Tron AE, Belmonte MA, Adam A, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. *Nat Commun.* 2018;9(1):5341.
47. Pop R, Shearstone JR, Shen Q, et al. A key commitment step in erythropoiesis is synchronized with the cell cycle clock through mutual inhibition between PU.1 and S-phase progression. *PLoS Biol.* 2010;8(9):e1000484.
48. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. *J Biol Chem.* 2002;277(32):28706-28713.
49. Auner HW, Beham-Schmid C, Dillon N, Sabbattini P. The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. *Blood.* 2010;116(18):3445-3455.
50. Macdonald A, Campbell DG, Toth R, McLauchlan H, Hastie CJ, Arthur JS. Pim kinases phosphorylate multiple sites on Bad and promote 14-3-3 binding and dissociation from Bcl-XL. *BMC Cell Biol.* 2006;7(1):1-14.
51. Kreis NN, Louwen F, Yuan J. The multifaceted p21 (Cip1/Waf1/CDKN1A) in cell differentiation, migration and cancer therapy. *Cancers (Basel).* 2019;11(9):1220.
52. Tourigny MR, Ursini-Siegel J, Lee H, et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. *Immunity.* 2002;17(2):179-189.
53. Sze DM-Y, Toellner K-M, García de Vinuesa C, Taylor DR, MacLennan ICM. Intrinsic constraint on plasmablast growth and extrinsic limits of plasma cell survival. *J Exp Med.* 2000;192(6):813-821.
54. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. *J Immunol.* 2002;169(8):4213-4221.
55. Raab MS, Thomas SK, Ocio EM, et al. The first-in-human study of the pan-PIM kinase inhibitor PIM447 in patients with relapsed and/or refractory multiple myeloma. *Leukemia.* 2019;33(12):2924-2933.
56. Marchalot A, Lambert J-M, Boyer F, et al. 2020. Splice switching oligonucleotide mediated gene knockdown in B cells and plasma cells. *bioRxiv.* doi:10.1101/2020.09.18.302984.
57. Zammarchi F, de Stanchina E, Bournazou E, et al. Antitumorigenic potential of STAT3 alternative splicing modulation. *Proc Natl Acad Sci USA.* 2011;108(43):17779-17784.

© 2022 by The American Society of Hematology